<code id='D56DF33B4B'></code><style id='D56DF33B4B'></style>
    • <acronym id='D56DF33B4B'></acronym>
      <center id='D56DF33B4B'><center id='D56DF33B4B'><tfoot id='D56DF33B4B'></tfoot></center><abbr id='D56DF33B4B'><dir id='D56DF33B4B'><tfoot id='D56DF33B4B'></tfoot><noframes id='D56DF33B4B'>

    • <optgroup id='D56DF33B4B'><strike id='D56DF33B4B'><sup id='D56DF33B4B'></sup></strike><code id='D56DF33B4B'></code></optgroup>
        1. <b id='D56DF33B4B'><label id='D56DF33B4B'><select id='D56DF33B4B'><dt id='D56DF33B4B'><span id='D56DF33B4B'></span></dt></select></label></b><u id='D56DF33B4B'></u>
          <i id='D56DF33B4B'><strike id='D56DF33B4B'><tt id='D56DF33B4B'><pre id='D56DF33B4B'></pre></tt></strike></i>

          knowledge

          knowledge

          author:focus    Page View:362
          Illustration of a red human heart with an EKG line in the middle. -- health coverage from STAT
          Adobe

          Just weeks after Novo Nordisk announced that its obesity drug Wegovy cut the risk of heart complications in a major trial, the company now has results from a different study showing the treatment can also benefit people with a common type of heart failure.

          The results, published Friday in the New England Journal of Medicine, found that among people with obesity and heart failure with preserved ejection fraction, or HFpEF, those taking Wegovy experienced greater improvements in symptoms and physical function compared with those on placebo. The improvements were greater than what’s been seen in trials of some other HFpEF treatments.

          advertisement

          Novo previously shared topline results in investor calls, but the new study contains the full findings, which are also being presented at the European Society of Cardiology conference this week.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          What does generative AI mean for health care? We asked experts
          What does generative AI mean for health care? We asked experts

          MikeReddyforSTATHealthcarecompaniesareracingtoincorporategenerativeAItoolsintotheirproductpipelinesa

          read more
          How doctors’ personal politics affect patients
          How doctors’ personal politics affect patients

          AlexHogan/STATThisessayisadaptedfrom“RandomActsofMedicine:TheHiddenForcesThatSwayDoctors,ImpactPatie

          read more
          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more

          Life sciences deals on track to hit lowest point since 2017

          AdobeIt’snosecretthatbiotechindustryfundinghasfallenfromitsCovidhighs.Butwithjustafewmonthsleftinthe